

- [CTVD Membership Update](#)
- [Annual CTVD Meeting](#)
- [Recent News](#)
- [CTVD Portal](#)
- [Upcoming Virtual Forums](#)
- [Research Community Update](#)
- [Early Career Scientist Award](#)
- [Visiting Scientist Program](#)
- [CTVD Advisory Council](#)
- [GH-VAP](#)
- [Upcoming Conferences](#)
- [Opportunities of Note](#)
- [Publications of Interest](#)
- [Feedback](#)

### CTVD Membership Update

For those of you who have been with us since the inception of CTVD, we are so thankful for your continued involvement; and fortunate to have you as part of the team. For those of you who are new to CTVD, welcome! We currently have 52 member institutions, with over 200 individual members, and are still growing.

### Save the Date

**4th Annual CTVD Meeting**  
June 20 - 22, 2018  
Seattle, Washington



The 4th CTVD Annual Meeting will be held at the Gates Foundation in Seattle, WA June 20-22, 2018! Research Community members will meet on June 20 and the general meeting will convene June 21-22. We look forward to this opportunity to discuss recent advances in the field of TB vaccine discovery. Additional details, and registration information, will be forthcoming. To view presentations from the 2017 annual meeting, please visit <https://portal.ctvd.co/ctvdmeetings>

### Recent News

The Division of Allergy, Immunology and Transplantation at NIAID recently approved a concept for FY 2019 entitled "Immune Mechanisms of Protection Against Mycobacterium tuberculosis Consortium (IMPAC-TB)", more info can be found here <https://www.niaid.nih.gov/grants-contracts/september-2017-dait-council-approved-concepts>.

### CTVD Portal

Have you missed previously recorded CTVD Virtual Forums or Meetings? Want to view documents from your Research Community? Access to the secure portal is available to CTVD members whose institution has signed the DMSA (data and materials sharing agreement). There is an expectation that data arising from CTVD services and GH-VAP services be shared in a manner consistent with the Data Sharing Principles. Visit the CTVD Portal, located in the upper right-hand corner of the CTVD home page, <https://www.ctvd.co>, to access all this information and more. Forgot your logon? Contact Ksenia Koon ([Ksenia.Koon@gatesfoundation.org](mailto:Ksenia.Koon@gatesfoundation.org)), CTVD Manager, for help.

### Upcoming Virtual Forums

The CTVD holds monthly virtual forms aimed at keeping our members informed of exciting advances in the field. If you have ideas for topics/speakers for upcoming virtual forums, please send them our way!

Note the upcoming virtual forum presenters and dates. All forums are held at 8am pacific time. Login details will be sent to CTVD members prior to each forum.

**Tuesday, October 31, 2017** — Keith Klugman

Presentation Title: "Recent advances in immunization against pulmonary pathogens"

**Thursday, November 16, 2017** — Matthew Albert

**Wednesday, December 6, 2017** — Danny Casimiro

**Thursday, January 18, 2018** — Peter Andersen

To view the most recent webinar, visit CTVD portal, located in the upper right-hand corner of the CTVD home page, at <https://www.ctvd.co>.

## Research Community Update

CTVD currently has six research communities. These research communities are involved in identifying and mapping critical research priorities for TB vaccine discovery and development. Each community is mandated with discussing the issues at hand and devising priority areas to address. We, at the Gates Foundation, champion these research communities and investigate avenues to fund these priorities. If you have questions about any of the research communities, please ask one of the co-chairs.

**Aerosol and Mucosal Vaccination:** Aurelio Bonavia | Steffen Stenger

**B-cells and Antibodies:** Bryan Charleston | Steve Porcelli

**Conventional T cells:** Helen Fletcher | Kevin Urdahl

**Donor-Unrestricted T Cells:** Dave Lewinsohn | Branch Moody

**Non-Human Primates:** Tricia Darrah | Dominick Laddy

**Whole Cell TB Vaccines:** Olivier Neyrolles

## Early Career Scientist Award

Today's early career scientists are essential to ensure that the field remains innovative, scientifically robust, and to infuse new ways of approaches to tackle the scientific challenges in order to develop a TB vaccine. The CTVD has implemented a process, the CTVD Early Career Scientist Award, to recognize the efforts of early career scientists who have made significant contributions to research in TB host-pathogen biology, immunology, and vaccinology. The Early Career Scientist award carries with it a travel grant to attend a TB-related conference. This award will cover expenses related to registration and travel (air flight, lodging, and meals).

All nominations must be submitted electronically via the link below. Nominations will not be accepted by email or by post. Please submit your nominations today!

<https://www.ctvd.co/Pages/EarlyCareerScientistAward.aspx>

Congratulations to our most recent Early Career Scientist Awardees!

### Early Career Scientist Award - October 2017



**Joshua Mattila, Ph.D.**

University of Pittsburgh, US

Expertise: Neutrophils, macrophages, nonhuman primate granulomas

Josh's overriding interest in immunology is understanding host responses to intracellular pathogens, and how these responses are modified by co-infections. He earned his PhD in 2006 from the University of Minnesota's Department of Entomology where he investigated innate immune responses to endosymbiotic rickettsiae and *Borrelia burgdorferi* in ticks. After this, he moved to the University of Pittsburgh for postdoctoral training with JoAnne Flynn where he used cynomolgus macaques to investigate how SIV changes anti-mycobacterial responses in individuals with latent tuberculosis. Josh's work focused on identifying changes in *Mycobacterium tuberculosis*-specific peripheral blood T cell cytokine expression over the course of disease reactivation. In addition to T cell cytokine responses, Josh has investigated nitric oxide and arginase expression by macrophages and neutrophils in granulomas, neutrophil protease expression in TB, and development of cell-type specific PET probes for tuberculosis. Josh's lab in University of Pittsburgh's Department of Infectious Diseases and Microbiology focuses on the interplay between macrophages, neutrophils, and T cells in granulomas, and how these interactions promote or inhibit protection in tuberculosis.

### Early Career Scientist Award - September 2017



**Javeed Shah, Ph.D.**

University of Washington, US

Expertise: Human immunology, Innate immunity, genetics, vaccines

Javeed obtained his M.D. from the University of Chicago Pritzker School of Medicine in 2005. During this time, he studied at the Vaccine Research Center of the National Institutes of Health. After completing his clinical training in internal medicine and infectious diseases, he joined the lab of Thomas Hawn at the University of Washington, where he focused on understanding the role of genetic variation within innate immune genes on the induction and maintenance of vaccine responses. Specifically, he studied a master immune regulatory protein, TOLLIP. After identification of a functionally active single nucleotide polymorphism in the TOLLIP promoter region that predicted TOLLIP deficiency in human macrophages, he evaluated the effect of TOLLIP deficiency on BCG-specific CD4+ T cell responses in 10-week-old South African infants. He discovered that infants with the hyperinflammatory TOLLIP-deficiency SNP developed fewer IL-2-producing

CD4+ T cells at 10 weeks of age. This work suggests that individuals with genetic factors that are associated with increased ongoing inflammation may have diminished capacity to maintain their vaccine immunity over time. His current work is focused on evaluating the role of TOLLIP on TB pathogenesis using both human and mouse models of infection, with the goal of true “bench-to-bedside” translational research on TB vaccines.

### Early Career Scientist Award - August 2017



#### **Iman Satti, Ph.D.**

The Jenner Institute, University of Oxford, UK  
Expertise: Human Immunology, Tuberculosis, vaccine development

Iman obtained her PhD from Karolinska Institute, Sweden, in 2004. She joined Professor McShane’s group at Oxford University in 2008. Iman is leading the human immunology work within the group. Her work focuses on evaluation of immunogenicity of candidate TB vaccines in humans. She has established immunological methods for evaluating mucosal and systemic responses in studies of aerosol vaccination and she led a project assessing whether alternating systemic and mucosal immunization overcomes anti-vector immunity. Iman is leading the evaluation of potential immunological correlates using samples taken from controlled human mycobacterial infection using BCG delivered both intradermally and by aerosol. She is also leading a case control correlate analysis on cases of M.tb infection vs controls in samples taken from infant and HIV efficacy trials, and on cases of TB disease in the HIV efficacy trial cohort. In relation to new vaccine development, Iman is investigating possible mechanisms underlying declining vaccines’ immunogenicity in TB endemic areas compared to studies in the UK. Iman is currently developing new chip cytometry methods that maximize the utilization of samples and allows more detailed studies of immune markers in both tissues and cells.

## Visiting Scientist Program

The Visiting Scientist Program (VSP) enables scientists from different CTVD member institutions to embrace new scientific concepts and gain experience in novel technologies with an overarching goal of promoting the exchange of ideas, expertise, and experiences. Through the VSP, scientists from CTVD member institutions from around the world are invited, as visiting scientists, to spend from 1 week to a maximum of 3 weeks and participate in established research studies in a laboratory of a CTVD member institution of their choice. Visiting scientists and the host scientists will jointly develop a coordinated agenda and training schedule, which is tailored to address their area of expertise and/or the specific techniques, instruments or innovations they want to learn.

Please visit <https://www.ctvd.co/Pages/VisitingScientistProgram.aspx> for more information and to apply!

## CTVD Advisory Council

The CTVD Advisory Council is comprised of the co-chairs from each of the six research communities, plus a representative from Aeras and TBVI. The Advisory Council meets semi-annually and guides the direction of CTVD.

## GH-VAP

The Global Health Vaccine Accelerator Platform (GH-VAP) program provides investigators with access to several specialized research platforms to accelerate vaccine discovery and translation across infectious disease areas. To learn more, visit GH-VAP at <https://www.qhvap.org>

## Upcoming Conferences

Please note the upcoming 5th Global Forum on TB Vaccines will be held in New Delhi in February 2018. For further details, please visit: [Global Forum](#)

## Opportunities of Note

Dr. Dan Barber’s lab at the NIH currently has a post-doctoral training position available. Interested candidates may contact Dr. Barber directly or see attached flyer for details. [Post-doctoral Training](#)

## Publications of Interest

Do you have an article that you think the CTVD community would enjoy reading? If so, please let us know. We welcome your contributions of publications of interest for upcoming newsletters and our website.

## Feedback

If you have questions or comments, please contact the CTVD program manager at [Ksenia.Koon@gatesfoundation.org](mailto:Ksenia.Koon@gatesfoundation.org)